Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPMY Astellas Pharma	$9.51 +1.1%	$9.59	$8.37 ▼ $13.14	N/A	0.23	122,390 shs	400,348 shs
ALXN Alexion Pharmaceuticals	$182.50	$182.82	$99.91 ▼ $187.45	$40.34B	1.25	3.31 million shs	10 shs
BGNE BeiGene		$194.32	$146.21 ▼ $248.16	$18.03B	0.57	337,092 shs	331,608 shs
GMAB Genmab A/S	$21.40 -2.1%	$21.04	$17.24 ▼ $28.56	$14.02B	0.94	1.25 million shs	1.25 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPMY Astellas Pharma	+1.06%	-0.94%	-2.56%	+7.58%	-5.84%
ALXN Alexion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+26.48%
GMAB Genmab A/S	-2.10%	+4.85%	-5.44%	+13.77%	-16.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPMY Astellas Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALXN Alexion Pharmaceuticals	1.3347 of 5 stars	0.0	0.0	0.0	3.8	0.6	1.7	1.9
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	4.1087 of 5 stars	3.3	5.0	0.0	0.0	3.4	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPMY Astellas Pharma	0.00	N/A	N/A	N/A
ALXN Alexion Pharmaceuticals	0.00	N/A	N/A	N/A
BGNE BeiGene	3.00	Buy	$274.20	∞ Upside
GMAB Genmab A/S	2.67	Moderate Buy	$37.80	76.64% Upside

Current Analyst Ratings Breakdown

Latest ALPMY, BGNE, GMAB, and ALXN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPMY Astellas Pharma	$12.56B	N/A	$1.82 per share	5.23	$5.52 per share	N/A
ALXN Alexion Pharmaceuticals	$6.07B	6.65	$22.81 per share	8.00	$53.24 per share	3.43
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
GMAB Genmab A/S	$3.12B	4.40	$1.48 per share	14.42	$8.04 per share	2.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPMY Astellas Pharma	$334.93M	$0.17	55.94	13.99	N/A	2.65%	16.55%	7.35%	7/29/2025 (Estimated)
ALXN Alexion Pharmaceuticals	$603.40M	$11.60	59.64	13.15	0.93	10.89%	23.43%	15.06%	N/A
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
GMAB Genmab A/S	$1.14B	$1.76	12.16	12.02	6.65	35.11%	18.08%	14.52%	8/14/2025 (Estimated)

Latest ALPMY, BGNE, GMAB, and ALXN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
4/25/2025	Q4 2025	ALPMY Astellas Pharma	$0.1474	$0.27	+$0.1226	$0.27	$3.02 billion	$3.22 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPMY Astellas Pharma	$0.35	3.68%	N/A	205.88%	N/A
ALXN Alexion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPMY Astellas Pharma	0.37	1.13	0.85
ALXN Alexion Pharmaceuticals	0.19	4.52	3.96
BGNE BeiGene	0.05	1.93	1.72
GMAB Genmab A/S	N/A	5.34	5.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPMY Astellas Pharma	N/A
ALXN Alexion Pharmaceuticals	82.94%
BGNE BeiGene	48.55%
GMAB Genmab A/S	7.07%

Insider Ownership

Company	Insider Ownership
ALPMY Astellas Pharma	N/A
ALXN Alexion Pharmaceuticals	4.03%
BGNE BeiGene	7.43%
GMAB Genmab A/S	1.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPMY Astellas Pharma	14,754	N/A	N/A	Not Optionable
ALXN Alexion Pharmaceuticals	3,837	221.02 million	N/A	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable

ALPMY, BGNE, GMAB, and ALXN Headlines

Recent News About These Companies

Genmab A/S (NASDAQ:GMAB) Upgraded at Wall Street Zen

July 12 at 2:02 AM | marketbeat.com

Analysts Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $37.60

July 11 at 2:45 AM | americanbankingnews.com

Truist Financial Remains a Buy on Genmab (GMAB)

July 10 at 2:35 AM | theglobeandmail.com

China Universal Asset Management Co. Ltd. Has $905,000 Stock Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

July 9 at 6:23 AM | marketbeat.com

14,361 Shares in Genmab A/S Sponsored ADR (NASDAQ:GMAB) Acquired by Callan Capital LLC

July 9 at 5:36 AM | marketbeat.com

Truist Financial Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

July 9 at 4:17 AM | americanbankingnews.com

Genmab A/S (NASDAQ:GMAB) Stock Price Expected to Rise, Truist Financial Analyst Says

July 8, 2025 | marketbeat.com

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Analysts

July 8, 2025 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

July 6, 2025 | marketbeat.com

Genmab Announces Changes to its Executive Committee

July 1, 2025 | globenewswire.com

Completion of Share Buy-back Program

June 30, 2025 | globenewswire.com

Genmab A/S (GMAB) Latest Stock News & Headlines - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Oppenheimer Asset Management Inc. Purchases 42,361 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)

June 25, 2025 | marketbeat.com

Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume - Here's Why

June 24, 2025 | marketbeat.com

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

June 23, 2025 | seekingalpha.com

Transactions in Connection with Share Buy-back Program

June 23, 2025 | globenewswire.com

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Acquired by QRG Capital Management Inc.

June 20, 2025 | marketbeat.com

GAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

June 19, 2025 | marketbeat.com

Capital Increase in Genmab as a Result of Employee Warrant Exercise

June 17, 2025 | globenewswire.com

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

June 17, 2025 | globenewswire.com

Transactions in Connection with Share Buy-back Program

June 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPMY, BGNE, GMAB, and ALXN Company Descriptions

Astellas Pharma OTCMKTS:ALPMY

$9.51 +0.10 (+1.06%)

As of 07/11/2025 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Alexion Pharmaceuticals NASDAQ:ALXN

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Genmab A/S NASDAQ:GMAB

$21.40 -0.46 (-2.10%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$21.44 +0.04 (+0.19%)

As of 07/11/2025 05:58 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time